ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and
safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated
Chronic Lymphocytic Leukemia.